X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of KYV-101 for the patients suffering from autoimmune diseases such as multiple sclerosis and myasthenia gravis.
Lead Product(s): KYV-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $366.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 12, 2024
Details:
The net proceeds will be used for the development of KYV-101 for the patients suffering from autoimmune diseases such as multiple sclerosis and myasthenia gravis.
Lead Product(s): KYV-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $319.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2024
Details:
KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate. It is under phase 1 clinical development for the treatment of Multiple Sclerosis.
Lead Product(s): KYV-101
Therapeutic Area: Neurology Product Name: KYV-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2024
Details:
KYV-101 is an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate for use in B cell-driven autoimmune diseases. It is being evaluated in phase 1 clinical trials for the treatment of patients with Refractory, Progressive Multiple Sclerosis.
Lead Product(s): KYV-101
Therapeutic Area: Neurology Product Name: KYV-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. It is being evaluated for the treatment of patients with refractory myasthenia gravis.
Lead Product(s): KYV-101
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
KYV-101 is a novel, fully human anti-CD19 CAR T-cell therapy for use in B cell-driven autoimmune diseases such as Myasthenia Gravis and represents an innovative approach to fighting autoimmune diseases by harnessing the power of the body's immune system.
Lead Product(s): KYV-101
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Under the agreement, Kyverna gains access to LentiVector® platform, the first commercially approved lentiviral-based gene delivery system, to use with any Kyverna product, including its anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201 which specifically target CD19.
Lead Product(s): KYV-101
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Oxford Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2023
Details:
KYV-101 is a novel, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for use in B cell-driven autoimmune diseases such as LN and represents an innovative approach to fighting autoimmune diseases by harnessing the power of the body's immune system.
Lead Product(s): KYV-101
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
The net proceeds will support clinical development of novel fully human CAR T-cell therapies, KYV-101 and KYV-201, specifically target CD19, a protein expressed on the surface of B cells which is involved in various types of autoimmune diseases including lupus nephritis.
Lead Product(s): KYV-101
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $145.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 03, 2023
Details:
KYV-101 is an autologous version of a novel fully human clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for use in B cell-driven autoimmune diseases.
Lead Product(s): KYV-101
Therapeutic Area: Nephrology Product Name: KYV-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
